Skip to main content
. 2019 Oct 10;33(2):334–344. doi: 10.1111/pcmr.12825

Figure 6.

Figure 6

Graphical summary of signaling in NRAS‐mutant melanoma cells treated with trametinib. FBXO42 KO in NRAS‐mutant melanoma cells leads trametinib resistance. This occurs by activation of the MAPK pathway together with TAK1 signaling through p38 activation. The combination of trametinib together with the TAK1 inhibitor, takinib, inhibits cellular proliferation